These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33212461)

  • 61. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.
    Kronenberger B; Berg T; Herrmann E; Hinrichsen H; Gerlach T; Buggisch P; Spengler U; Goeser T; Nasser S; Wursthorn K; Pape GR; Hopf U; Zeuzem S
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):639-46. PubMed ID: 17625432
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Side effects of medical therapy for chronic hepatitis C.
    Shiffman ML
    Ann Hepatol; 2004; 3(1):5-10. PubMed ID: 15118573
    [TBL] [Abstract][Full Text] [Related]  

  • 63. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.
    Reiser M; Buggisch P; Grossmann J; Koop K; Wursthorn K; Schmiegel W
    Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1299-304. PubMed ID: 14624153
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease.
    Adinolfi LE; Durante Mangoni E; Andreana A
    Am J Gastroenterol; 2001 Feb; 96(2):607-8. PubMed ID: 11232725
    [No Abstract]   [Full Text] [Related]  

  • 65. [Use of anxiolytics and antidepressants before and after treatment with interferon-alpha and ribavirin in patients with hepatitis C].
    García-Toro M; Vilella Martorell A; Carral Martínez M; Jimeno Beltrán T; Román Ruiz del Moral Y; Pradas Guerrero C; Gili Planas M; Roca Bennasar M
    Gastroenterol Hepatol; 2011 Apr; 34(4):307-8. PubMed ID: 21376422
    [No Abstract]   [Full Text] [Related]  

  • 66. The importance of a prior psychiatric examination in pegylated interferon and ribavirin combination treatment for chronic hepatitis C.
    Kuhara K; Ide T; Uchimura N; Kumashiro R; Arinaga T; Miyajima I; Murashima S; Ogata K; Kuwahara R; Amano K; Fujimoto Y; Sakai K; Ishii K; Morita Y; Shirachi M; Sata M
    Kurume Med J; 2012; 59(3-4):39-44. PubMed ID: 23823013
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
    Juarez-Navarro A; Vera-de-León L; Navarro JM; Chirino-Sprung R; Díaz-Hernandez M; Casillas-Davila L; Dehesa-Violante M
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):317-22. PubMed ID: 16082419
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin.
    Kerl K; Negro F; Lübbe J
    Br J Dermatol; 2003 Sep; 149(3):656. PubMed ID: 14511009
    [No Abstract]   [Full Text] [Related]  

  • 69. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment.
    Vázquez-López F; Manjón-Haces JA; Pérez-Alvarez R; Pérez-Oliva N
    Br J Dermatol; 2004 May; 150(5):1046-7; author reply 1047. PubMed ID: 15149535
    [No Abstract]   [Full Text] [Related]  

  • 70. [Dysacusia associated with pegylated-interferon and ribavirin combination therapy during chronic hepatitis C treatment: a report of two cases].
    Jia YH; Gao SJ; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jan; 20(1):67-8. PubMed ID: 22489302
    [No Abstract]   [Full Text] [Related]  

  • 71. Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C.
    Hoffmann RM; Berg T; Teuber G; Prümmer O; Leifeld L; Jung MC; Spengler U; Zeuzem S; Hopf U; Pape GR
    Z Gastroenterol; 1999 Aug; 37(8):715-23. PubMed ID: 10494606
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Retinal vascular complications associated with interferon-ribavirin therapy for chronic hepatitis C: A population-based study.
    Lai CH; Yang YH; Chen PC; King YC; Liu CY
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):191-198. PubMed ID: 29210149
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
    Fouad YM; Khalaf H; Ibraheem H; Rady H; Helmy AK
    Int J Infect Dis; 2012 Jan; 16(1):e67-71. PubMed ID: 22115957
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Neuropsychiatric disorders in HCV-infected people--own observations].
    Czarnecki M; Inglot M; Małyszczak K; Rymer W; Jańczak G; Pawłowski T; Gładysz A
    Przegl Epidemiol; 2005; 59(2):431-8. PubMed ID: 16190551
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C.
    Fontana RJ
    Dig Dis; 2000; 18(3):107-16. PubMed ID: 11279329
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
    Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
    de Lédinghen V; Trimoulet P; Winnock M; Foucher J; Bourlière M; Desmorat H; Canva V; Capron D; Lévy S; Mion F; Mannant PR; Chêne G; Fleury H; Couzigou P; Bernard PH;
    J Hepatol; 2002 May; 36(5):672-80. PubMed ID: 11983451
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Side effects of therapy for chronic hepatitis C.
    Russo MW; Fried MW
    Gastroenterology; 2003 May; 124(6):1711-9. PubMed ID: 12761728
    [No Abstract]   [Full Text] [Related]  

  • 80. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.